Abstract
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); moreover, 680,000 people developed multidrug-resistant TB (MDRTB).
Methods: Currently available anti-MDR and XDR regimens are long-lasting and expensive, need high adherence and are undermined by a high frequency of adverse drug events, thus leading to a low success rate; furthermore, in the last 50 years only two new molecules, bedaquiline (BDQ) and delamanid, have been approved and released for the treatment of MDR-TB.
Results: BDQ, patent number US 7,498,343B2, is a diarylquinoline anti-mycobacterial drug, active regardless of the state of MTB; in fact, its efficacy is conserved against replicating and non-replicating bacilli, despite extracellular or intracellular location. BDQ has been approved by the Food and Drug Administration (FDA) only for combination treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB), in adult patients, when an effective treatment cannot be provided otherwise due to resistance or poor tolerability; however, due to high bactericidal activity, BDQ may be used in future to treat extrapulmonary tuberculosis and Mycobacterium other than tuberculosis (MOTT) infection.
Conclusion: BDQ may play a major role to get closer to TB eradication and to ensure higher retention in care, even in fully susceptible MTB strains and against non-replicating mycobacteria in latent-TB, providing an alternative to standard regimen.
Keywords: Tuberculosis, Bedaquiline, MDR-TB, intracellular, standard regimen, strains.
Graphical Abstract
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Related Books
Marine Biopharmaceuticals: Scope and Prospects
COVID 19 – Monitoring with IoT Devices
Frontiers in Clinical Drug Research: Anti-Infectives
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
Recent Trends and The Future of Antimicrobial Agents - Part 2
COVID-19: Origin, Impact and Management (Part 2)
Frontiers in Anti-Infective Drug Discovery
COVID-19: Origin, Impact and Management, Part 1
Toll-Like Receptors in Vector-borne Diseases
49
14